JVM, a subsidiary of Hanmi Science, announced on the 6th that its consolidated operating profit last year was 30.7 billion won, representing a 3.0% increase compared to the previous year.
During the same period, sales increased by 1.5% compared to the previous year, recording 159.4 billion won. Net profit for the period grew by 9.9% to 28.8 billion won. Both sales and operating profit are the highest on record. To secure future growth engines, a total of 9.8 billion won was invested in research and development, accounting for 6.2% of consolidated sales.
JVM is a corporation that develops customized pharmaceutical dispensing automation solutions. The company cited the global market expansion of its flagship products as the background for this performance growth. These include 'MENITH,' a next-generation automatic dispenser that utilizes robotic arms to enhance work efficiency, and 'COUNTMATE,' a fully automatic vial dispensing system.
JVM, incorporated into Hanmi Science in 2016, is focusing on R&D and production for new product development. Hanmi Pharmaceutical manages overseas operations while OnlinePharm takes charge of domestic operations. Currently, JVM supplies its equipment to 60 countries through 34 global partners of Hanmi Pharmaceutical.
Lee Dong-hwan, CEO of JVM, noted, "We were able to expand the scale of our global exports based on our customer-oriented automation solutions and unique technological capabilities," and added, "We will continue to develop automation solutions that meet the specific dispensing needs of each region in collaboration with local partners to increase our global market share."